NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 763,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "44e4039b-148d-40ad-a960-be1b6759f71b",
"title": "Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments",
"description": "Estimated Earnings Per Share: Analysts projected a loss of $0.16 per share, while actual loss was $0.74 per share.Estimated Net Income: The estimated net loss",
"keywords": "GuruFocus, Article, News, GuruFocus Research, GALT",
"snippet": "On March 29, 2024, Galectin Therapeutics Inc (GALT, Financial), a leader in the development of therapeutics targeting galectin proteins, released its 8-K filing...",
"url": "https://www.gurufocus.com/news/2401174/galectin-therapeutics-inc-galt-reports-2023-financial-results-and-business-developments",
"image_url": "https://static.gurufocus.com/logos/0C000008LZ.png?5",
"language": "en",
"published_at": "2024-03-29T13:11:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GALT",
"name": "Galectin Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 144.58676,
"sentiment_score": 0.117467,
"highlights": [
{
"highlight": "On March 29, 2024, <em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> (GALT, Financial), a leader in the development of therapeutics targeting galectin proteins, released its 8-K filing, disclosing its financial results for the year ended December 31, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> is a clinical-stage biopharmaceutical company focused on the development of new therapies for fibrotic disease, cancer, and other diseases. Its lead galectin-3 inhibitor, belapectin (GR-MD-02), has shown promise in preclinical models to reverse liver fibrosis and cirrhosis.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Despite not generating revenue, <em>Galectin</em> <em>Therapeutics</em> has managed to reduce its general and administrative expenses and has benefitted from a $10 million credit facility provided by Chairman Richard Uihlein.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "With a focus on developing novel therapies for chronic liver disease and cancer, <em>Galectin</em> <em>Therapeutics</em> aims to leverage its scientific and development expertise to efficiently advance its clinical programs.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "For detailed financial tables and further information on <em>Galectin</em> <em>Therapeutics</em> Inc's financial performance, readers are encouraged to view the full 8-K filing.\n\nExplore the complete 8-K earnings release (here) from <em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> for further details.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> (GALT) Reports 2023 Financial Results and Business Developments",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "90f057ba-0037-4a95-b42c-b438c55d1013",
"title": "Q4 2023 Iterum Therapeutics PLC Earnings Call Transcript",
"description": "Mar 28, 2024 / 12:30PM GMTOperator Hello, everyone, and welcome to the Iterum Therapeutics fourth quarter and full year 2023 financial results and business upda",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:ITRM",
"snippet": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nHello, everyone, and welcome to the Iterum Therapeutics fourth quarter and full year 2023 financial results and business...",
"url": "https://www.gurufocus.com/news/2400190/q4-2023-iterum-therapeutics-plc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T05:04:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ITRM",
"name": "Iterum Therapeutics plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 165.57605,
"sentiment_score": 0.459433,
"highlights": [
{
"highlight": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nHello, everyone, and welcome to the <em>Iterum</em> <em>Therapeutics</em> fourth quarter and full year 2023 financial results and business update. My name is Emily, and I'll be coordinating your call. (Operator Instructions)\n\n\n\nI will now turn the call over to our host, Louise Barrett, Senior Vice President of Legal Affairs.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Louise Barrett - <em>Iterum</em> <em>Therapeutics</em> <em>plc</em> - SVP, Legal Affairs\n\n\n\nThank you, Emily. Good morning and welcome to <em>Iterum</em> <em>Therapeutics</em>' fourth quarter and full year 2023 financial results and business update conference call. Our press release for our fourth quarter and full results was issued earlier this morning and can be found on our website.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Iterum</em> <em>Therapeutics</em> <em>PLC</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "04b73c1c-446d-4f0b-b9b8-8de1a9738979",
"title": "Q4 2023 Agile Therapeutics Inc Earnings Call Transcript",
"description": "Mar 28, 2024 / 12:30PM GMTOperator Good morning, and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2023 financial results conference call. Plea",
"keywords": "GuruFocus, Article, News, GuruFocus Research, OTCPK:AGRX",
"snippet": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nGood morning, and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2023 financial results conference call....",
"url": "https://www.gurufocus.com/news/2400187/q4-2023-agile-therapeutics-inc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T05:04:13.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AGRX",
"name": "Agile Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 143.15182,
"sentiment_score": 0.452967,
"highlights": [
{
"highlight": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nGood morning, and welcome to the <em>Agile</em> <em>Therapeutics</em> Fourth Quarter and Full Year 2023 financial results conference call. Please note, today's event is being recorded I would now like to turn the conference over to Matt Reilly, Head of Investor Relations. Please go ahead.",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Matthew Riley - <em>Agile</em> <em>Therapeutics</em> <em>Inc</em> - Head of Investor Relations, Corporate Communications\n\n\n\nHello, everyone, and welcome to today's conference call to discuss our fourth quarter and full year 2023 financial results and corporate update.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Agile</em> <em>Therapeutics</em> <em>Inc</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "aea8dda3-1e74-4f88-922c-88fe2f9445ad",
"title": "Q4 2023 Inhibikase Therapeutics Inc Earnings Call Transcript",
"description": "Mar 28, 2024 / 12:00PM GMTOperator Ladies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics fourth-quarter and full-ye",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:IKT",
"snippet": "Mar 28, 2024 / 12:00PM GMT\n\nOperator\n\n\n\nLadies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics fourth-quarter and fu...",
"url": "https://www.gurufocus.com/news/2400175/q4-2023-inhibikase-therapeutics-inc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T05:03:59.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IKT",
"name": "Inhibikase Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 161.53055,
"sentiment_score": 0.536333,
"highlights": [
{
"highlight": "Greetings, and welcome to <em>Inhibikase</em> <em>Therapeutics</em> fourth-quarter and full-year 2023 financial results. At this time, all participants will be in listen-only mode. A question-and-answer session will follow the formal presentation. Please note that today's conference is being recorded.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "Alex Lobo - <em>Inhibikase</em> <em>Therapeutics</em> <em>Inc</em> - Investor Relations\n\n\n\nThank you, operator. Good morning, and welcome to <em>Inhibikase</em> <em>Therapeutics</em> fourth-quarter and full-year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Inhibikase</em> <em>Therapeutics</em> <em>Inc</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "8efe575a-80bf-4300-82d2-080d469ec8e8",
"title": "Eco Wave Power Global : Files its Annual Report on Form 20-F for the Year Ended December 31, 2023, and Announces Significant Progress in Full Year 2023 Financial and Operational Results - Form 6-K -Ma",
"description": "Eco Wave Power Files its Annual Report on Form 20-F for the Year Ended December 31, 2023, and Announces Significant Progress in\n Full Year 2023 Financial and Operational Results\n \n ...",
"keywords": "Markets",
"snippet": "Eco Wave Power Files its Annual Report on Form 20-F for the Year Ended December 31, 2023, and Announces Significant Progress in\n\nFull Year 2023 Financial and Op...",
"url": "https://www.marketscreener.com/quote/stock/ECO-WAVE-POWER-GLOBAL-AB-124328864/news/Eco-Wave-Power-Global-Files-its-Annual-Report-on-Form-20-F-for-the-Year-Ended-December-31-2023-a-46319958/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-29T13:02:07.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "WAVE",
"name": "Eco Wave Power Global AB (publ)",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Utilities",
"match_score": 73.601074,
"sentiment_score": 0.331827,
"highlights": [
{
"highlight": "of Final License for the Construction of its First Commercial Project in Portugal\n\nStockholm, Sweden, March 29, 2024 - <em>Eco</em> <em>Wave</em> <em>Power</em> <em>Global</em> <em>AB</em> (<em>publ</em>) (\"Eco <em>Wave</em> Power\" or the \"Company\") (<em>Nasdaq</em>: <em>WAVE</em>), a leading, publicly traded onshore <em>wave</em> energy technology company, today announced that it has filed its annual report on Form 20-F for the fiscal",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "● In 2023, Eco <em>Wave</em> Power also conducted several feasibility studies that enabled us and our clients to explore new markets for <em>wave</em> energy implementation.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "While Eco <em>Wave</em> Power had an eventful year, in the financial markets, clean energy stocks, including <em>WAVE</em> Stock, did not perform well, as we believe high interest rates and lagging efforts to combat climate change have impacted the sector.",
"sentiment": 0.4548,
"highlighted_in": "main_text"
},
{
"highlight": "I would like to finish by saying that as the founder and CEO of Eco <em>Wave</em> Power, and one of the largest shareholders of <em>WAVE</em> stock, I am disappointed by the performance of the <em>WAVE</em> stock on the financial market (the company's market cap is currently below its cash position).",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Eco</em> <em>Wave</em> <em>Power</em> <em>Global</em> <em>AB</em> (<em>publ</em>)\n\nEco <em>Wave</em> Power is a leading onshore <em>wave</em> energy technology company that developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "The EWP-EDF One station project marks the first grid-connected <em>wave</em> energy system in Israeli history.\n\nEco <em>Wave</em> Power will soon commence the installation of its newest pilot in AltaSea's premises in the Port of Los Angeles and its first MW scale <em>wave</em> energy power station in Portugal, Europe.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Eco <em>Wave</em> Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program. The Company has also received the \"Global Climate Action Award\" from the United Nations.\n\nEco <em>Wave</em> Power's American Depositary Shares (<em>WAVE</em>) are traded on the Nasdaq Capital Market.",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "References and links to websites have been provided as a convenience and the information contained on such websites is not incorporated by reference into this press release.\n\n6\n\n<em>Eco</em> <em>Wave</em> <em>Power</em> <em>Global</em> <em>AB</em> (<em>publ</em>)\n\nCONSOLIDATED STATEMENTS OF FINANCIAL POSITION\n\nDecember 31 Note 2023 2022 in USD thousands Assets CURRENT ASSETS: Cash and cash equivalents",
"sentiment": 0.4824,
"highlighted_in": "main_text"
},
{
"highlight": "2,208 2,043 EQUITY: 12 Common shares 98 98 Share premium 23,121 23,121 Foreign currency translation reserve (2,275 ) (2,061 ) Accumulated deficit (12,994 ) (11,284 ) Capital and reserves attributable to parent company shareholders 7,950 9,874 Non-controlling interest (149 ) - TOTAL EQUITY 7,801 9,874 TOTAL LIABILITIES AND EQUITY 10,009 11,917\n\n7\n\n<em>Eco</em>",
"sentiment": 0.2885,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Wave</em> <em>Power</em> <em>Global</em> <em>AB</em> (<em>publ</em>)\n\nCONSOLIDATED STATEMENTS OF LOSS\n\nYear ended December 31 Note 2023 2022 2021 in USD thousands REVENUES 15d 306 26 31 COST OF REVENUES (59 ) (22 ) (27 ) GROSS PROFIT 247 4 4 OPERATING EXPENSES Research and development expenses 15e (519 ) (898 ) (670 ) Sales and marketing expenses 15f (375 ) (461 ) (485 ) General and administrative",
"sentiment": -0.4995,
"highlighted_in": "main_text"
},
{
"highlight": "Eco <em>Wave</em> Power Global : Files its Annual Report on Form 20-F for the Year Ended December 31, 2023, and Announces Significant Progress in Full Year 2023 Financial and Operational Results - Form 6-K -Ma",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
},
{
"symbol": "ENPH",
"name": "Enphase Energy, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 8.282923,
"sentiment_score": 0.8828,
"highlights": [
{
"highlight": "According to CNN, Plug Power shares have slipped 63% this year, <em>Enphase</em> <em>Energy</em> shares have plunged 60%, SolarEdge Technologies shares have declined 71% and NextEra Energy shares have slid 29%, showing that even the largest and most resilient energy companies have taken a hit by the financial situation in 2023.",
"sentiment": 0.8828,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "0fb73f7c-7462-4c56-bee6-6a1167b4b8d9",
"title": "SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results By Investing.com",
"description": "SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results",
"keywords": "",
"snippet": "Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results\n\nMarch 29, 2024\n\nSAB-142 Phase 1...",
"url": "https://www.investing.com/news/press-releases/sab-biotherapeutics-reports-full-year-2023-operating-and-financial-results-93CH-3357998",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-29T11:28:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "EDIT",
"name": "Editas Medicine, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.029329,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Lucera, a 30-year veteran of the biotechnology and medical device industry, has held executive positions at several healthcare companies, most recently as Chief Financial Officer of <em>Editas</em> <em>Medicine</em> (NASDAQ: ).\n\n(NASDAQ: ).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "c9c8268c-7312-4b32-b89f-b4e685779a75",
"title": "Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023 By Investing.com",
"description": "Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023",
"keywords": "",
"snippet": "Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared...",
"url": "https://www.investing.com/news/press-releases/guardion-health-sciences-announces-financial-results-for-the-year-ended-december-31-2023-93CH-3357984",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-03-29T10:28:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "BEST",
"name": "BEST Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 6.961092,
"sentiment_score": 0.305325,
"highlights": [
{
"highlight": "Recent Developments in 2024\n\nAgreement to Sell Activ Nutritional, LLC\n\nOn January 30, 2024, the Company entered into an Equity Purchase Agreement (the Purchase Agreement) with Doctor's <em>Best</em> <em>Inc</em>., a Delaware corporation, for the sale of all of the outstanding equity interests of Activ Nutritional, LLC (Activ) for aggregate cash consideration of $17.2",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "Doctor's <em>Best</em> <em>Inc</em>. is a wholly-owned subsidiary of Kingdomway USA Corp., the U.S. subsidiary holding company of Xiamen Kingdomway Group Company (XKDW), which is publicly listed on the Shenzhen Stock Exchange.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the successful completion of the sale of Activ to Doctor's <em>Best</em>",
"sentiment": 0.339,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>., the use of the proceeds received from the sale, the Company's ability to continue to fund its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, supply chain disruptions",
"sentiment": -0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GHSI",
"name": "Guardion Health Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 121.78165,
"sentiment_score": 0.2665,
"highlights": [
{
"highlight": "Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022\n\nHOUSTON, TEXAS, March 29, 2024 (GLOBE NEWSWIRE) -- <em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>GHSI</em>) (Guardion or the Company), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2023.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>.\n\n<em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>. (<em>Nasdaq</em>: <em>GHSI</em>) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>.,¯Contact:\n\[email protected]\n\n\n\nPhone: 1-800 873-5141 Ext 208",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardion</em> <em>Health</em> <em>Sciences</em> Announces Financial Results for the Year Ended December 31, 2023 By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "002626.SZ",
"name": "Xiamen Kingdomway Group Company",
"exchange": null,
"exchange_long": null,
"country": "cz",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.715092,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., the U.S. subsidiary holding company of <em>Xiamen</em> <em>Kingdomway</em> <em>Group</em> <em>Company</em> (XKDW), which is publicly listed on the Shenzhen Stock Exchange.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "4d60b995-bb1d-4b4d-9417-15fbb6ccc7a8",
"title": "VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm",
"description": "PHILADELPHIA, March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. on behalf of the company's shareholders.\n\n \n \n ...",
"keywords": "Markets",
"snippet": "PHILADELPHIA, March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) (\"Viridian\") on behal...",
"url": "https://www.marketscreener.com/quote/stock/VIRIDIAN-THERAPEUTICS-INC-34091127/news/VIRIDIAN-Kaskela-Law-LLC-Announces-Investigation-of-Viridian-Therapeutics-Inc-VRDN-and-Encourage-46319947/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-29T13:01:10.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "VRDN",
"name": "Viridian Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 140.50908,
"sentiment_score": 0.22165,
"highlights": [
{
"highlight": "PHILADELPHIA, March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating <em>Viridian</em> <em>Therapeutics</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>VRDN</em>) (\"Viridian\") on behalf of the company's shareholders.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 715 – 1740 or (484) 229 – 0750, or by email ([email protected] / [email protected]) or online at https://kaskelalaw.com/cases/<em>viridian</em>-<em>therapeutics</em>/ , for additional information about this investigation and their legal rights and options.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "View original content to download multimedia:https://www.prnewswire.com/news-releases/viridian-shareholder-alert-kaskela-law-llc-announces-investigation-of-<em>viridian</em>-<em>therapeutics</em>-<em>inc</em>-vrdn-and-encourages-investors-to-contact-the-firm-302103244.html\n\nSOURCE Kaskela Law LLC",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "VIRIDIAN Kaskela Law LLC Announces Investigation of <em>Viridian</em> <em>Therapeutics</em>, <em>Inc</em>. (VRDN) and Encourages Investors to Contact the Firm",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "7218d2d1-1e45-4298-be33-d6ccab2b8474",
"title": "PLUG LAWSUIT ALERT: The Gross Law Firm Notifies Plug Power Inc. Investors of a Class Action Lawsuit and Upcoming Deadline -March 29, 2024 at 05:46 am EDT",
"description": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Plug Power Inc. .\n\n \n \n \n \n ...",
"keywords": "Markets",
"snippet": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Plug Power Inc. (NASDAQ: PLUG).\n\nShareholders who pur...",
"url": "https://www.marketscreener.com/quote/stock/PLUG-POWER-INC-10490/news/PLUG-LAWSUIT-ALERT-The-Gross-Law-Firm-Notifies-Plug-Power-Inc-Investors-of-a-Class-Action-Lawsuit-46319065/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-29T09:46:23.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "PLUG",
"name": "Plug Power Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 84.26904,
"sentiment_score": -0.12422,
"highlights": [
{
"highlight": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of <em>Plug</em> <em>Power</em> <em>Inc</em>. (<em>NASDAQ</em>: <em>PLUG</em>).\n\nShareholders who purchased shares of PLUG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/<em>plug</em>-<em>power</em>-<em>inc</em>-loss-submission-form-3/?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Register your information here: https://securitiesclasslaw.com/securities/<em>plug</em>-<em>power</em>-<em>inc</em>-loss-submission-form-3/?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nThe Gross Law Firm\n\n15 West 38th Street, 12th floor\n\nNew York, NY, 10018\n\nEmail: [email protected]\n\nPhone: (646) 453-8903\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/plug-lawsuit-alert-the-gross-law-firm-notifies-<em>plug</em>-<em>power</em>-<em>inc</em>-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302103111",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "PLUG LAWSUIT ALERT: The Gross Law Firm Notifies <em>Plug</em> <em>Power</em> <em>Inc</em>. Investors of a Class Action Lawsuit and Upcoming Deadline -March 29, 2024 at 05:46 am EDT",
"sentiment": -0.5719,
"highlighted_in": "title"
}
]
},
{
"symbol": "PLUN.DE",
"name": "Plug Power Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Industrials",
"match_score": 70.40212,
"sentiment_score": -0.12422,
"highlights": [
{
"highlight": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of <em>Plug</em> <em>Power</em> <em>Inc</em>. (NASDAQ: PLUG).\n\nShareholders who purchased shares of PLUG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/<em>plug</em>-<em>power</em>-<em>inc</em>-loss-submission-form-3/?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Register your information here: https://securitiesclasslaw.com/securities/<em>plug</em>-<em>power</em>-<em>inc</em>-loss-submission-form-3/?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nThe Gross Law Firm\n\n15 West 38th Street, 12th floor\n\nNew York, NY, 10018\n\nEmail: [email protected]\n\nPhone: (646) 453-8903\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/plug-lawsuit-alert-the-gross-law-firm-notifies-<em>plug</em>-<em>power</em>-<em>inc</em>-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302103111",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "PLUG LAWSUIT ALERT: The Gross Law Firm Notifies <em>Plug</em> <em>Power</em> <em>Inc</em>. Investors of a Class Action Lawsuit and Upcoming Deadline -March 29, 2024 at 05:46 am EDT",
"sentiment": -0.5719,
"highlighted_in": "title"
}
]
},
{
"symbol": "PLUG.MX",
"name": "Plug Power Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Industrials",
"match_score": 70.40465,
"sentiment_score": -0.12422,
"highlights": [
{
"highlight": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of <em>Plug</em> <em>Power</em> <em>Inc</em>. (NASDAQ: PLUG).\n\nShareholders who purchased shares of PLUG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT US HERE:\n\nhttps://securitiesclasslaw.com/securities/<em>plug</em>-<em>power</em>-<em>inc</em>-loss-submission-form-3/?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Register your information here: https://securitiesclasslaw.com/securities/<em>plug</em>-<em>power</em>-<em>inc</em>-loss-submission-form-3/?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nThe Gross Law Firm\n\n15 West 38th Street, 12th floor\n\nNew York, NY, 10018\n\nEmail: [email protected]\n\nPhone: (646) 453-8903\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/plug-lawsuit-alert-the-gross-law-firm-notifies-<em>plug</em>-<em>power</em>-<em>inc</em>-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302103111",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "PLUG LAWSUIT ALERT: The Gross Law Firm Notifies <em>Plug</em> <em>Power</em> <em>Inc</em>. Investors of a Class Action Lawsuit and Upcoming Deadline -March 29, 2024 at 05:46 am EDT",
"sentiment": -0.5719,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "4ade989a-e295-4154-ad7a-459f21cbdd50",
"title": "Fox Factory Holding Corp. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 22, 2024 to Discuss Your Rights - FOXF -March 29, 2024 at 05:46 am EDT",
"description": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fox Factory Holding Corp. .\n\n \n \n \n ...",
"keywords": "Markets",
"snippet": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fox Factory Holding Corp. (NASDAQ: FOXF).\n\nShareholde...",
"url": "https://www.marketscreener.com/quote/stock/FOX-FACTORY-HOLDING-CORP-13870449/news/Fox-Factory-Holding-Corp-Securities-Fraud-Class-Action-Lawsuit-Pending-Contact-The-Gross-Law-Firm-46319043/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-29T09:46:17.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "FOXF",
"name": "Fox Factory Holding Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 116.83935,
"sentiment_score": -0.2714,
"highlights": [
{
"highlight": "NEW YORK, March 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of <em>Fox</em> <em>Factory</em> <em>Holding</em> <em>Corp</em>. (<em>NASDAQ</em>: <em>FOXF</em>).\n\nShareholders who purchased shares of FOXF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nThe Gross Law Firm\n\n15 West 38th Street, 12th floor\n\nNew York, NY, 10018\n\nEmail: [email protected]\n\nPhone: (646) 453-8903\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/<em>fox</em>-<em>factory</em>-<em>holding</em>-<em>corp</em>-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-april-22-2024-to-discuss-your-rights",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Fox</em> <em>Factory</em> <em>Holding</em> <em>Corp</em>. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 22, 2024 to Discuss Your Rights - FOXF -March 29, 2024 at 05:46 am EDT",
"sentiment": -0.765,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "9423e378-a61d-4e1e-93cc-884cbecc22b8",
"title": "Pacific Premier Bancorp, Inc. to Announce First Quarter 2024 Financial Results on April 24, 2024",
"description": "Pacific Premier Bancorp, Inc. , the holding company of Pacific Premier Bank, announced today that it will issue its first quarter 2024 financial results before the market opens on Wednesday, April...",
"keywords": "Markets",
"snippet": "Pacific Premier Bancorp, Inc. (Nasdaq: PPBI) (\"Pacific Premier\"), the holding company of Pacific Premier Bank, announced today that it will issue its first quar...",
"url": "https://www.marketscreener.com/quote/stock/PACIFIC-PREMIER-BANCORP-I-10522/news/Pacific-Premier-Bancorp-Inc-to-Announce-First-Quarter-2024-Financial-Results-on-April-24-2024-46319942/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-29T13:01:05.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.257358,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "Pacific Premier Bank also offers a wide array of loan products, such as commercial business loans, lines of credit, SBA loans, commercial real estate loans, agribusiness loans, <em>franchise</em> lending, home equity lines of credit, and construction loans.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "09e77045-fccb-4567-b4bd-dbf8f044774f",
"title": "16 APRIL 2024 AT 15:00 (CEST) - Form 6-K -March 29, 2024 at 08:34 am EDT",
"description": "16 APRIL 2024 AT 15:00 \n \n \n at Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.\n \n \n \n AGENDA\n \n \n 1.Election of the chairman of the...",
"keywords": "Markets",
"snippet": "16 APRIL 2024 AT 15:00 (CEST)\n\nat Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.\n\nAGENDA\n\n1.Election of the chairman of the meeting\n\n2.The ...",
"url": "https://www.marketscreener.com/quote/stock/EVAXION-BIOTECH-A-S-118683095/news/16-APRIL-2024-AT-15-00-CEST-Form-6-K-46319836/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-29T12:34:11.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "EVAX",
"name": "Evaxion Biotech A/S",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 33.584335,
"sentiment_score": -0.121233,
"highlights": [
{
"highlight": "16 APRIL 2024 AT 15:00 (CEST)\n\nat <em>Evaxion</em> <em>Biotech</em> <em>A</em>/<em>S</em>, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Miscellaneous\n\nHørsholm, Denmark, 26 March 2024 The board of directors of <em>Evaxion</em> <em>Biotech</em> <em>A</em>/<em>S</em> /s/ Marianne Søgaard Marianne Søgaard Chairperson of the board of directors\n\n7\n\nFurther information\n\nAdoption requirements\n\nThe proposal under the agenda's item 7a may be adopted by a majority of not less than two thirds of all votes cast and of the share capital",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Prior to founding <em>Evaxion</em> <em>Biotech</em> <em>A</em>/<em>S</em>, he was a Medical Director within the area of Companion Diagnostics for Medical Prognosis A/S from 2009 to 2011, and he was a Medical Advisor within the area of cancer and biopharmaceuticals for AstraZeneca from 2008 to 2009. Dr. Møller began this career at Servier Pharmaceuticals as Marketing Manager.\n\nDr.",
"sentiment": -0.6597,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "71ed6a88-721b-4d65-8fd8-7c4c20092b8a",
"title": "BurgerFi to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024 By Investing.com",
"description": "BurgerFi to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024",
"keywords": "",
"snippet": "FORT LAUDERDALE, Fla., March 29, 2024 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (BurgerFi), owner of one of the nation's leading fas...",
"url": "https://www.investing.com/news/press-releases/burgerfi-to-report-fourth-quarter-and-fiscal-year-2023-financial-results-on-april-1-2024-93CH-3358005",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-03-29T12:12:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 11.492212,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "Anthony's is a premium pizza and wing brand with 60 restaurants (59 corporate-owned casual restaurant locations and 1 dual brand <em>franchise</em> location), as of January 1, 2024.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "69691978-5c1c-4a9c-a166-203b9cb6801a",
"title": "Molecular Templates GAAP EPS of -$0.73, revenue of $7.02M (NASDAQ:MTEM)",
"description": "Molecular Templates (MTEM) reports Q4 financial results and business update: GAAP EPS of -$0.73, revenue of $7.02M (+169.0% YoY).",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4085290-molecular-templates-gaap-eps-of-0_73-revenue-of-7_02m",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-29T12:35:57.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MTEM",
"name": "Molecular Templates, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 113.57713,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Molecular</em> <em>Templates</em> GAAP EPS of -$0.73, revenue of $7.02M (<em>NASDAQ:MTEM</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "901b8e32-8469-4b77-9999-b1112b3bc50f",
"title": "Galectin Therapeutics GAAP EPS of -$0.74 (NASDAQ:GALT)",
"description": "Galectin Therapeutics has reported an FY 2023 GAAP EPS of -$0.74.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4085288-galectin-therapeutics-gaap-eps-of-0_74",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-29T12:33:36.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "GALT",
"name": "Galectin Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 125.94964,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Galectin</em> <em>Therapeutics</em> GAAP EPS of -$0.74 (<em>NASDAQ:GALT</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "49021a38-3e90-4604-8d86-bb69b18f65ba",
"title": "Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update By Investing.com",
"description": "Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update",
"keywords": "",
"snippet": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates (NASDAQ: ), Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmac...",
"url": "https://www.investing.com/news/press-releases/molecular-templates-inc-reports-fourth-quarter-2023-financial-results-and-business-update-93CH-3358018",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-29T12:32:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MTEM",
"name": "Molecular Templates, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 141.50284,
"sentiment_score": 0.1428,
"highlights": [
{
"highlight": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- <em>Molecular</em> <em>Templates</em> (NASDAQ: ), Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>MTEM</em>, <em>Molecular</em> <em>Templates</em>, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Templates</em>\n\n<em>Molecular</em> <em>Templates</em> is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em> disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, when or if used in this press release, the words may, could, should, continue, anticipate, potential, believe, estimate, appears, expect, intend, plan, predict and similar expressions and their variants, as they relate to <em>Molecular</em> <em>Templates</em> may identify forward-looking statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to the following: the continued availability of financing on commercially reasonable terms, whether <em>Molecular</em> <em>Templates</em>' cash resources will be sufficient to fund its continuing operations; the",
"sentiment": 0.1016,
"highlighted_in": "main_text"
},
{
"highlight": "results of MTEM's ongoing clinical studies and the ability to effectively operate MTEM, and those risks identified under the heading Risk Factors in <em>Molecular</em> <em>Templates</em>' filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the year ended December 31, 2023 and any subsequent reports filed with the SEC.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Any forward-looking statements contained in this press release speak only as of the date hereof, and <em>Molecular</em> <em>Templates</em> specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.\n\nContacts:[email protected]\n\nSource: <em>Molecular</em> <em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em>, <em>Inc</em>. Reports Fourth Quarter 2023 Financial Results and Business Update By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "612d690d-acb7-4923-a79c-536a79cc5707",
"title": "Gannett Announces Nomination of Independent Candidate to Board of Directors By Investing.com",
"description": "Gannett Announces Nomination of Independent Candidate to Board of Directors",
"keywords": "",
"snippet": "Digital Product Leader Maha Al-Emam Nominated to Join the Board in June\n\nMCLEAN, Va.--(BUSINESS WIRE)--Gannett Co., Inc. (\"Gannett\", \"we\", \"us\", \"our\", or the \"...",
"url": "https://www.investing.com/news/press-releases/gannett-announces-nomination-of-independent-candidate-to-board-of-directors-93CH-3358016",
"image_url": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
"language": "en",
"published_at": "2024-03-29T12:28:06.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 10.109301,
"sentiment_score": 0.148,
"highlights": [
{
"highlight": "Discovery (NASDAQ: ) Global Brand <em>Franchise</em> and also formerly a digital product leader at Apple (NASDAQ: ), Inc., NBCUniversal Media, LLC, and Bloomberg, LP, for election to the Company's Board of Directors at its upcoming annual meeting of stockholders on June 3, 2024. If elected, Ms. Al-Emam will join the Board of Directors as of such date.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Discovery's Global Brand <em>Franchise</em>. Prior to that, she spent nearly seven years at Apple, Inc., most recently as the Managing Director for Digital Strategy and Product at Apple Retail Worldwide. Prior to her time at Apple, Ms.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "f7b1201f-b5f0-46f9-829b-d3335b00c378",
"title": "Революция искусственного интеллекта и NVDA: могут наступить трудные времена.",
"description": "",
"keywords": "",
"snippet": "Финансовые тенденции даже новых и интересных технологий иногда могут привести к длите?...",
"url": "https://smart-lab.ru/blog/1002673.php",
"image_url": "https://smart-lab.ru/uploads/2024/images/03/07/69/2024/03/29/8564a389f8.webp",
"language": "ru",
"published_at": "2024-03-29T12:25:26.000000Z",
"source": "smart-lab.ru",
"relevance_score": null,
"entities": [
{
"symbol": "BOTZ",
"name": "Global X Robotics & Artificial Intelligence ETF",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "etf",
"industry": "N/A",
"match_score": 64.5251,
"sentiment_score": null,
"highlights": [
{
"highlight": "Действительно, если бы Nvidia была страной, она бы входила в десятку крупнейших экономик мира.Тем не менее, небольшое предостережение: тенденции обычно не идут вверх или вниз по прямым линиям без значительных перерывов.В отчёте «Глобальные ставки и денежные потоки» за март был опубликован этот график биржевого фонда искусственного интеллекта:BOTZ, тикер <em>Global</em>",
"sentiment": null,
"highlighted_in": "main_text"
},
{
"highlight": "<em>X</em> <em>Robotics</em> & <em>Artificial</em> <em>Intelligence</em> <em>ETF</em>, демонстрирует явное пятиволновое снижение с 2021 по 2022 год.",
"sentiment": null,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "66b818ea-817c-42c3-9238-dd6041027542",
"title": "Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update",
"description": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...",
"keywords": "Nasdaq:MTEM, Molecular Templates, Inc.",
"snippet": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharma...",
"url": "https://www.globenewswire.com/news-release/2024/03/29/2854722/0/en/Molecular-Templates-Inc-Reports-Fourth-Quarter-2023-Financial-Results-and-Business-Update.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/1af4d1b3-0a20-4be1-a846-79d8df413603",
"language": "en",
"published_at": "2024-03-29T12:21:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MTEM",
"name": "Molecular Templates, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 149.46875,
"sentiment_score": 0.156864,
"highlights": [
{
"highlight": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- <em>Molecular</em> <em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>MTEM</em>, “<em>Molecular</em> <em>Templates</em>,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Templates</em>\n\n<em>Molecular</em> <em>Templates</em> is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em> disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, when or if used in this press release, the words “may,” “could,” “should,” “continue”, “anticipate,” “potential”, “believe,” “estimate,” “appears”, “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to <em>Molecular</em> <em>Templates</em> may identify forward-looking statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to the following: the continued availability of financing on commercially reasonable terms, whether <em>Molecular</em> <em>Templates</em>’ cash resources will be sufficient to fund its continuing operations; the",
"sentiment": 0.1016,
"highlighted_in": "main_text"
},
{
"highlight": "results of MTEM’s ongoing clinical studies and the ability to effectively operate MTEM, and those risks identified under the heading “Risk Factors” in <em>Molecular</em> <em>Templates</em>’ filings with the Securities and Exchange Commission (the “SEC”), including its Form 10-K for the year ended December 31, 2023 and any subsequent reports filed with the SEC.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Any forward-looking statements contained in this press release speak only as of the date hereof, and <em>Molecular</em> <em>Templates</em> specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.\n\nContacts:\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em>, <em>Inc</em>. Reports Fourth Quarter 2023 Financial Results and Business Update",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1316,
"sentiment_avg": 0.2775198933293276
}
]
}
Other details
Country
- us
- 5,275